Laboratory and clinical evaluation of RU 28965 in respiratory infections

Yoshiteru Shigeno, Tomokazu Kakazu, Kazunori Tamaki, Hiroshi Fukuhara, Mustsuko Miyagi, Hiroki Nakamura, Hiroshi Kaneshima, Katsuyoshi Shimoji, Keizo Kitsukawa, Kenji Mori, Yutoku Kinjo, Atsushi Saito, Isamu Nakasone, Masayuki Taira, Nobuchika Kusano, Seitetsu Hokama, Yuei Irabu, Morio Oshiro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

RU 28965, a new macrolide antibiotic, was basically and clinically evaluated with the following results. 1. Antimicrobial activity: the minimum Inhibitory concentrations (MICs) of RU 28965 against a total 134 strains consisting of 12 standard strains and 122 clinical isolates (6 species) were compared with those of erythromycin (EM) and cefaclor (CCL). RU 28965's antibacterial activity was equally or half as potent as that of EM against S.aureus, S.pneumoniae, B.catarrhalis and 1/2 or 1/4 as potent against H. influenzae. On the other hand, both antibiotics were poor against K.pneumoniae and P.aensginosa. 2. Clinical efficacy: RU 28965 was administered at a dailydose of 300 mg for 3~14 days to 15 patients with various respiratory infections. Clinical response was good 9, fair 2, poor 2 and not assessable 1; one dropped out. The overall efficacy rate was 69.2%(9/13 cases). Subjective and objective symptoms, hematological and biochemical data and renal functions were checked before and after administration of RU 28965. Three patients showed adverse reactions: diarrhea, eosinophilia, and minimal elevation of both S-GOT and S-GPT in 1 each. We therefore conclude that RU 28965 is a useful antibiotic in treating patients with respiratory infections.

Original languageEnglish
Pages (from-to)461-473
Number of pages13
JournalChemotherapy
Volume36
DOIs
Publication statusPublished - 1988
Externally publishedYes

Fingerprint

Roxithromycin
Respiratory Tract Infections
Erythromycin
Anti-Bacterial Agents
Pneumonia
Cefaclor
Macrolides
Eosinophilia
Microbial Sensitivity Tests
Human Influenza
Diarrhea
Kidney

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Shigeno, Y., Kakazu, T., Tamaki, K., Fukuhara, H., Miyagi, M., Nakamura, H., ... Oshiro, M. (1988). Laboratory and clinical evaluation of RU 28965 in respiratory infections. Chemotherapy, 36, 461-473. https://doi.org/10.11250/chemotherapy1953.36.Supplement4_461

Laboratory and clinical evaluation of RU 28965 in respiratory infections. / Shigeno, Yoshiteru; Kakazu, Tomokazu; Tamaki, Kazunori; Fukuhara, Hiroshi; Miyagi, Mustsuko; Nakamura, Hiroki; Kaneshima, Hiroshi; Shimoji, Katsuyoshi; Kitsukawa, Keizo; Mori, Kenji; Kinjo, Yutoku; Saito, Atsushi; Nakasone, Isamu; Taira, Masayuki; Kusano, Nobuchika; Hokama, Seitetsu; Irabu, Yuei; Oshiro, Morio.

In: Chemotherapy, Vol. 36, 1988, p. 461-473.

Research output: Contribution to journalArticle

Shigeno, Y, Kakazu, T, Tamaki, K, Fukuhara, H, Miyagi, M, Nakamura, H, Kaneshima, H, Shimoji, K, Kitsukawa, K, Mori, K, Kinjo, Y, Saito, A, Nakasone, I, Taira, M, Kusano, N, Hokama, S, Irabu, Y & Oshiro, M 1988, 'Laboratory and clinical evaluation of RU 28965 in respiratory infections', Chemotherapy, vol. 36, pp. 461-473. https://doi.org/10.11250/chemotherapy1953.36.Supplement4_461
Shigeno, Yoshiteru ; Kakazu, Tomokazu ; Tamaki, Kazunori ; Fukuhara, Hiroshi ; Miyagi, Mustsuko ; Nakamura, Hiroki ; Kaneshima, Hiroshi ; Shimoji, Katsuyoshi ; Kitsukawa, Keizo ; Mori, Kenji ; Kinjo, Yutoku ; Saito, Atsushi ; Nakasone, Isamu ; Taira, Masayuki ; Kusano, Nobuchika ; Hokama, Seitetsu ; Irabu, Yuei ; Oshiro, Morio. / Laboratory and clinical evaluation of RU 28965 in respiratory infections. In: Chemotherapy. 1988 ; Vol. 36. pp. 461-473.
@article{2cbcb6e2ebda4c018df04b6a4a2bf78c,
title = "Laboratory and clinical evaluation of RU 28965 in respiratory infections",
abstract = "RU 28965, a new macrolide antibiotic, was basically and clinically evaluated with the following results. 1. Antimicrobial activity: the minimum Inhibitory concentrations (MICs) of RU 28965 against a total 134 strains consisting of 12 standard strains and 122 clinical isolates (6 species) were compared with those of erythromycin (EM) and cefaclor (CCL). RU 28965's antibacterial activity was equally or half as potent as that of EM against S.aureus, S.pneumoniae, B.catarrhalis and 1/2 or 1/4 as potent against H. influenzae. On the other hand, both antibiotics were poor against K.pneumoniae and P.aensginosa. 2. Clinical efficacy: RU 28965 was administered at a dailydose of 300 mg for 3~14 days to 15 patients with various respiratory infections. Clinical response was good 9, fair 2, poor 2 and not assessable 1; one dropped out. The overall efficacy rate was 69.2{\%}(9/13 cases). Subjective and objective symptoms, hematological and biochemical data and renal functions were checked before and after administration of RU 28965. Three patients showed adverse reactions: diarrhea, eosinophilia, and minimal elevation of both S-GOT and S-GPT in 1 each. We therefore conclude that RU 28965 is a useful antibiotic in treating patients with respiratory infections.",
author = "Yoshiteru Shigeno and Tomokazu Kakazu and Kazunori Tamaki and Hiroshi Fukuhara and Mustsuko Miyagi and Hiroki Nakamura and Hiroshi Kaneshima and Katsuyoshi Shimoji and Keizo Kitsukawa and Kenji Mori and Yutoku Kinjo and Atsushi Saito and Isamu Nakasone and Masayuki Taira and Nobuchika Kusano and Seitetsu Hokama and Yuei Irabu and Morio Oshiro",
year = "1988",
doi = "10.11250/chemotherapy1953.36.Supplement4_461",
language = "English",
volume = "36",
pages = "461--473",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Laboratory and clinical evaluation of RU 28965 in respiratory infections

AU - Shigeno, Yoshiteru

AU - Kakazu, Tomokazu

AU - Tamaki, Kazunori

AU - Fukuhara, Hiroshi

AU - Miyagi, Mustsuko

AU - Nakamura, Hiroki

AU - Kaneshima, Hiroshi

AU - Shimoji, Katsuyoshi

AU - Kitsukawa, Keizo

AU - Mori, Kenji

AU - Kinjo, Yutoku

AU - Saito, Atsushi

AU - Nakasone, Isamu

AU - Taira, Masayuki

AU - Kusano, Nobuchika

AU - Hokama, Seitetsu

AU - Irabu, Yuei

AU - Oshiro, Morio

PY - 1988

Y1 - 1988

N2 - RU 28965, a new macrolide antibiotic, was basically and clinically evaluated with the following results. 1. Antimicrobial activity: the minimum Inhibitory concentrations (MICs) of RU 28965 against a total 134 strains consisting of 12 standard strains and 122 clinical isolates (6 species) were compared with those of erythromycin (EM) and cefaclor (CCL). RU 28965's antibacterial activity was equally or half as potent as that of EM against S.aureus, S.pneumoniae, B.catarrhalis and 1/2 or 1/4 as potent against H. influenzae. On the other hand, both antibiotics were poor against K.pneumoniae and P.aensginosa. 2. Clinical efficacy: RU 28965 was administered at a dailydose of 300 mg for 3~14 days to 15 patients with various respiratory infections. Clinical response was good 9, fair 2, poor 2 and not assessable 1; one dropped out. The overall efficacy rate was 69.2%(9/13 cases). Subjective and objective symptoms, hematological and biochemical data and renal functions were checked before and after administration of RU 28965. Three patients showed adverse reactions: diarrhea, eosinophilia, and minimal elevation of both S-GOT and S-GPT in 1 each. We therefore conclude that RU 28965 is a useful antibiotic in treating patients with respiratory infections.

AB - RU 28965, a new macrolide antibiotic, was basically and clinically evaluated with the following results. 1. Antimicrobial activity: the minimum Inhibitory concentrations (MICs) of RU 28965 against a total 134 strains consisting of 12 standard strains and 122 clinical isolates (6 species) were compared with those of erythromycin (EM) and cefaclor (CCL). RU 28965's antibacterial activity was equally or half as potent as that of EM against S.aureus, S.pneumoniae, B.catarrhalis and 1/2 or 1/4 as potent against H. influenzae. On the other hand, both antibiotics were poor against K.pneumoniae and P.aensginosa. 2. Clinical efficacy: RU 28965 was administered at a dailydose of 300 mg for 3~14 days to 15 patients with various respiratory infections. Clinical response was good 9, fair 2, poor 2 and not assessable 1; one dropped out. The overall efficacy rate was 69.2%(9/13 cases). Subjective and objective symptoms, hematological and biochemical data and renal functions were checked before and after administration of RU 28965. Three patients showed adverse reactions: diarrhea, eosinophilia, and minimal elevation of both S-GOT and S-GPT in 1 each. We therefore conclude that RU 28965 is a useful antibiotic in treating patients with respiratory infections.

UR - http://www.scopus.com/inward/record.url?scp=85004482986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004482986&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.36.Supplement4_461

DO - 10.11250/chemotherapy1953.36.Supplement4_461

M3 - Article

AN - SCOPUS:85004482986

VL - 36

SP - 461

EP - 473

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -